BCL2L12 and melanoma: A first example illustrating this concept is the chr19:49665874 C > T (GRCh38/hg38) mutation, which was described in 2013 as a synonymous p.Phe17Phe mutation targeting the BCL2L12 oncogene in 4% of melanoma skin cancers [14].